LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Metabolic Implications of Immune Checkpoint Proteins in Cancer.

    Stirling, Elizabeth R / Bronson, Steven M / Mackert, Jessica D / Cook, Katherine L / Triozzi, Pierre L / Soto-Pantoja, David R

    Cells

    2022  Volume 11, Issue 1

    Abstract: Expression of immune checkpoint proteins restrict immunosurveillance in the tumor microenvironment; thus, FDA-approved checkpoint inhibitor drugs, specifically PD-1/PD-L1 and CTLA-4 inhibitors, promote a cytotoxic antitumor immune response. Aside from ... ...

    Abstract Expression of immune checkpoint proteins restrict immunosurveillance in the tumor microenvironment; thus, FDA-approved checkpoint inhibitor drugs, specifically PD-1/PD-L1 and CTLA-4 inhibitors, promote a cytotoxic antitumor immune response. Aside from inflammatory signaling, immune checkpoint proteins invoke metabolic reprogramming that affects immune cell function, autonomous cancer cell bioenergetics, and patient response. Therefore, this review will focus on the metabolic alterations in immune and cancer cells regulated by currently approved immune checkpoint target proteins and the effect of costimulatory receptor signaling on immunometabolism. Additionally, we explore how diet and the microbiome impact immune checkpoint blockade therapy response. The metabolic reprogramming caused by targeting these proteins is essential in understanding immune-related adverse events and therapeutic resistance. This can provide valuable information for potential biomarkers or combination therapy strategies targeting metabolic pathways with immune checkpoint blockade to enhance patient response.
    MeSH term(s) Diet ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Proteins/metabolism ; Leukocytes/drug effects ; Leukocytes/metabolism ; Microbiota/drug effects ; Neoplasms/metabolism
    Chemical Substances Immune Checkpoint Inhibitors ; Immune Checkpoint Proteins
    Language English
    Publishing date 2022-01-05
    Publishing country Switzerland
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2661518-6
    ISSN 2073-4409 ; 2073-4409
    ISSN (online) 2073-4409
    ISSN 2073-4409
    DOI 10.3390/cells11010179
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis.

    Mackert, Jessica D / Stirling, Elizabeth R / Wilson, Adam S / Westwood, Brian / Zhao, Dawen / Lo, Hui-Wen / Metheny-Barlow, Linda / Cook, Katherine L / Lesser, Glenn J / Soto-Pantoja, David R

    bioRxiv : the preprint server for biology

    2023  

    Abstract: The presence of cell surface protein CD47 allows cancer cells to evade innate and adaptive immune surveillance resulting in metastatic spread. CD47 binds to and activates SIRPα on the surface of myeloid cells, inhibiting their phagocytic activity. On the ...

    Abstract The presence of cell surface protein CD47 allows cancer cells to evade innate and adaptive immune surveillance resulting in metastatic spread. CD47 binds to and activates SIRPα on the surface of myeloid cells, inhibiting their phagocytic activity. On the other hand, CD47 binds the matricellular protein Thrombospondin-1, limiting T-cell activation. Thus, blocking CD47 is a potential therapeutic strategy for preventing brain metastasis. To test this hypothesis, breast cancer patient biopsies were stained with antibodies against CD47 to determine differences in protein expression. An anti-CD47 antibody was used in a syngeneic orthotopic triple-negative breast cancer model, and CD47 null mice were used in a breast cancer brain metastasis model by intracardiac injection of the E0771-Br-Luc cell line. Immunohistochemical staining of patient biopsies revealed an 89% increase in CD47 expression in metastatic brain tumors compared to normal adjacent tissue (p ≤ 0.05). Anti-CD47 treatment in mice bearing brain metastatic 4T1br3 orthotopic tumors reduced tumor volume and tumor weight by over 50% compared to control mice (p ≤ 0.05) and increased IBA1 macrophage/microglia marker 5-fold in tumors compared to control (p ≤ 0.05). Additionally, CD47 blockade increased the M1/M2 macrophage ratio in tumors 2.5-fold (p ≤ 0.05). CD47 null mice had an 89% decrease in metastatic brain burden (p ≤ 0.05) compared to control mice in a brain metastasis model. Additionally, RNA sequencing revealed several uniquely expressed genes and significantly enriched genes related to tissue development, cell death, and cell migration tumors treated with anti-CD47 antibodies. Thus, demonstrating that CD47 blockade affects cancer cell and tumor microenvironment signaling to limit metastatic spread and may be an effective therapeutic for triple-negative breast cancer brain metastasis.
    Language English
    Publishing date 2023-07-25
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.07.25.550566
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Combination of the anthocyanidins malvidin and peonidin attenuates LPS-mediated inflammatory gene expression in primary human adipocytes

    Mackert, Jessica D / Michael K. McIntosh

    Nutrition research. 2016,

    2016  

    Abstract: We recently demonstrated that California table grapes and a methanol-extractable, polyphenol-rich fraction decreased adiposity, insulin resistance, or markers of inflammation in high-fat fed mice. Malvidin and peonidin glycosides were the two most ... ...

    Abstract We recently demonstrated that California table grapes and a methanol-extractable, polyphenol-rich fraction decreased adiposity, insulin resistance, or markers of inflammation in high-fat fed mice. Malvidin and peonidin glycosides were the two most abundant anthocyanins in the polyphenol-rich fraction. We hypothesized that a blood borne combination of anthocyanidins malvidin and peonidin derived from intestinal β-glycosidase metabolism of these two anthocyanins are responsible, in part, for the beneficial health effects observed in vivo. Therefore, we supplemented primary human adipocytes with malvidin or peonidin, alone or together, followed by acute lipopolysaccharide (LPS) treatment. Neither peonidin nor malvidin alone consistently decreased the expression of several inflammatory genes. However, supplementing adipocytes with an equal combination of malvidin plus peonidin followed by LPS treatment decreased the mRNA levels of interleukin (IL)-6, IL-1β, IL-8, monocyte chemoattractant protein-1, toll-like receptor-2, tumor necrosis factor alpha, cyclooxygenase-2, and interferon gamma-induced protein-10. The highest combination dose of malvidin plus peonidin decreased or increased the expression of protein tyrosine phosphatase-1B and hormone sensitive lipase, respectively, genes encoding proteins associated with insulin resistance or lipolysis. These data indicate that a combination of malvidin plus peonidin have potentiating interactions that reduce inflammatory gene expression; however, in vivo studies are needed to support these in vitro data.
    Keywords adipocytes ; adiposity ; anthocyanins ; blood ; carboxylic ester hydrolases ; chemokine CCL2 ; gene expression ; genes ; human cell lines ; in vivo studies ; inflammation ; insulin resistance ; interferons ; interleukin-1beta ; interleukin-8 ; lipolysis ; lipopolysaccharides ; malvidin ; messenger RNA ; mice ; prostaglandin synthase ; protein synthesis ; table grapes ; Toll-like receptor 2 ; tumor necrosis factor-alpha ; tyrosine
    Language English
    Size p. .
    Publishing place Elsevier Inc.
    Document type Article
    Note Pre-press version
    ZDB-ID 582432-1
    ISSN 1879-0739 ; 0271-5317
    ISSN (online) 1879-0739
    ISSN 0271-5317
    DOI 10.1016/j.nutres.2016.11.003
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  4. Article ; Online: Combination of the anthocyanidins malvidin and peonidin attenuates lipopolysaccharide-mediated inflammatory gene expression in primary human adipocytes.

    Mackert, Jessica D / McIntosh, Michael K

    Nutrition research (New York, N.Y.)

    2016  Volume 36, Issue 12, Page(s) 1353–1360

    Abstract: We recently demonstrated that California table grapes and a methanol-extractable, polyphenol-rich fraction decreased adiposity, insulin resistance, or markers of inflammation in high-fat fed mice. Malvidin and peonidin glycosides were the 2 most abundant ...

    Abstract We recently demonstrated that California table grapes and a methanol-extractable, polyphenol-rich fraction decreased adiposity, insulin resistance, or markers of inflammation in high-fat fed mice. Malvidin and peonidin glycosides were the 2 most abundant anthocyanins in the polyphenol-rich fraction. We hypothesized that a blood borne combination of anthocyanidins malvidin and peonidin derived from intestinal β-glycosidase metabolism of these 2 anthocyanins are responsible, in part, for the beneficial health effects observed in vivo. Therefore, we supplemented primary human adipocytes with malvidin or peonidin, alone or together, followed by acute lipopolysaccharide (LPS) treatment. Neither peonidin nor malvidin alone consistently decreased the expression of several inflammatory genes. However, supplementing adipocytes with an equal combination of malvidin plus peonidin followed by LPS treatment decreased the mRNA levels of interleukin (IL)-6, IL-1β, IL-8, monocyte chemoattractant protein-1, toll-like receptor-2, tumor necrosis factor alpha, cyclooxygenase-2, and interferon gamma-induced protein-10. The highest combination dose of malvidin plus peonidin decreased or increased the expression of protein tyrosine phosphatase-1B and hormone sensitive lipase, respectively, genes encoding proteins associated with insulin resistance or lipolysis. These data indicate that a combination of malvidin plus peonidin have potentiating interactions that reduce inflammatory gene expression; however, in vivo studies are needed to support these in vitro data.
    Language English
    Publishing date 2016-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 582432-1
    ISSN 1879-0739 ; 0271-5317
    ISSN (online) 1879-0739
    ISSN 0271-5317
    DOI 10.1016/j.nutres.2016.11.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top